ObsEva SA (NASDAQ:OBSV)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Wednesday. They presently have a $27.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 210.70% from the stock’s current price.

Several other brokerages have also recently weighed in on OBSV. Zacks Investment Research cut shares of ObsEva SA from a “hold” rating to a “sell” rating in a research report on Saturday, August 19th. Royal Bank Of Canada started coverage on shares of ObsEva SA in a research report on Thursday, September 14th. They set an “outperform” rating and a $22.00 price target for the company. Finally, Leerink Swann reissued an “outperform” rating and set a $18.00 price target on shares of ObsEva SA in a research report on Wednesday, August 16th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $23.00.

ObsEva SA (OBSV) traded up 0.81% during trading on Wednesday, reaching $8.69. 254 shares of the company traded hands. ObsEva SA has a 12-month low of $6.77 and a 12-month high of $14.18. The firm’s 50 day moving average price is $7.67 and its 200 day moving average price is $7.67. The firm’s market capitalization is $257.49 million.

ObsEva SA (NASDAQ:OBSV) last announced its quarterly earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.13). During the same quarter last year, the firm earned ($0.30) EPS. Equities research analysts expect that ObsEva SA will post ($2.38) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “HC Wainwright Reiterates Buy Rating for ObsEva SA (OBSV)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/06/hc-wainwright-reiterates-buy-rating-for-obseva-sa-obsv.html.

Institutional investors and hedge funds have recently made changes to their positions in the business. Baker Avenue Asset Management LP purchased a new stake in shares of ObsEva SA in the 1st quarter worth about $104,000. Paloma Partners Management Co purchased a new stake in shares of ObsEva SA in the 1st quarter worth about $131,000. Iguana Healthcare Management LLC purchased a new stake in shares of ObsEva SA in the 1st quarter worth about $260,000. Spark Investment Management LLC purchased a new stake in shares of ObsEva SA in the 1st quarter worth about $518,000. Finally, Nexthera Capital LP purchased a new stake in shares of ObsEva SA in the 1st quarter worth about $521,000. 48.46% of the stock is owned by institutional investors and hedge funds.

ObsEva SA Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Analyst Recommendations for ObsEva SA (NASDAQ:OBSV)

Receive News & Stock Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related stocks with our FREE daily email newsletter.